CSF ACR 2022 - Congress Preview (RA)
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Editor’s Picks<br />
13:00–<br />
15:00<br />
1395<br />
1396<br />
1401<br />
1419<br />
1420<br />
1427<br />
1429<br />
1431<br />
15:15–<br />
15:25<br />
1586<br />
15:45–<br />
15:55<br />
1588<br />
16:15–<br />
16:25<br />
1590<br />
POSTER SESSION<br />
<strong>RA</strong> – DIAGNOSIS, MANIFESTATIONS, AND<br />
OUTCOMES POSTER III<br />
Comparative Safety of Janus Kinase Inhibitors and Tumor<br />
Necrosis Factor Inhibitors in Patients Undergoing Treatment for<br />
Rheumatoid Arthritis<br />
Yao-Fan Fang<br />
Risk of Hospitalized Infections in Older Elderly Rheumatoid<br />
Arthritis Patients Treated with Biological/Targeted Synthetic<br />
DMARDs: Evaluation Using Data from a Japanese Claims<br />
Database<br />
Masayoshi Harigai<br />
Relationship Between Disease Activity and Adverse Events of<br />
Interest in Patients with <strong>RA</strong> on Tofacitinib or TNF Inhibitors: Post<br />
Hoc Analysis of a Phase 3b/4 Randomized Safety Study<br />
George A Karpouzas<br />
Time to Discontinuation and Effectiveness with Baricitinib<br />
in Rheumatoid Arthritis: 12-Month European Data from a<br />
Multinational, Prospective, Observational Study<br />
Rieke Alten<br />
Outcomes in Patients with Rheumatoid Arthritis Initiating<br />
Monotherapy with Etanercept, Adalimumab, or Janus Kinase<br />
Inhibitors<br />
Dimitrios Pappas<br />
Impact of Upadacitinib versus Abatacept on Individual Disease<br />
Outcomes in Patients with Rheumatoid Arthritis and Inadequate<br />
Responses to Biologic DMARDs<br />
Ronald F. Van Vollenhoven<br />
Acute Cardiovascular Events Risk in Rheumatoid Arthritis<br />
Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide<br />
Cohort Study: RELATION Study<br />
Jacques-Eric Gottenberg<br />
Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis<br />
Giovanni Adami<br />
O<strong>RA</strong>L SESSION<br />
<strong>RA</strong> – TREATMENT I: SWITCHING OR<br />
DISCONTINUATION OF THE<strong>RA</strong>PIES<br />
Sustained Remission Following the Discontinuation of<br />
Tofacitinib in Patients with Rheumatoid Arthritis (XANADU<br />
Study): A Multicenter, Prospective, and Randomized Controlled<br />
Study<br />
Satoshi Kubo<br />
O<strong>RA</strong>L SESSION<br />
<strong>RA</strong> – TREATMENT I: SWITCHING OR<br />
DISCONTINUATION OF THE<strong>RA</strong>PIES<br />
Outcomes of Etanercept and Janus Kinase Inhibitor Treatment<br />
After First-line Use of Adalimumab in Patients with Rheumatoid<br />
Arthritis<br />
Dimitrios Pappas<br />
O<strong>RA</strong>L SESSION<br />
<strong>RA</strong> – TREATMENT I: SWITCHING OR<br />
DISCONTINUATION OF THE<strong>RA</strong>PIES<br />
Pain and Treatment Switching Among Patients in the<br />
CorEvitasTM Rheumatoid Arthritis Registry<br />
Joshua Baker<br />
Monday, 14 November <strong>2022</strong><br />
09:30–<br />
09:40<br />
L03<br />
10:15–<br />
10:25<br />
L06<br />
13:00–<br />
15:00<br />
1765<br />
13:00–<br />
15:00<br />
1984<br />
1985<br />
1995<br />
2008<br />
2015<br />
O<strong>RA</strong>L SESSION<br />
LATE-BREAKING ABST<strong>RA</strong>CTS (L01–L06)<br />
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid<br />
Arthritis<br />
Paul Emery<br />
O<strong>RA</strong>L SESSION<br />
LATE-BREAKING ABST<strong>RA</strong>CTS (L01–L06)<br />
Risk of Extended Major Adverse Cardiovascular Event<br />
Endpoints with Tofacitinib vs TNF Inhibitors in Patients with<br />
Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4<br />
Randomized Safety Study<br />
Maya Buch<br />
POSTER SESSION<br />
EPIDEMIOLOGY AND PUBLIC HEALTH POSTER III<br />
Safety of the Recombinant Herpes Zoster Vaccine in Patients<br />
with Rheumatoid Arthritis Treated with JAKi Drugs<br />
Ana Pons<br />
POSTER SESSION<br />
<strong>RA</strong> – TREATMENT POSTER IV<br />
Malignancies Risk in Rheumatoid Arthritis Patients Treated with<br />
Tofacitinib or TNF Inhibitors, a National Study: RELATION Study<br />
Jacques-eric Gottenberg<br />
The BEGIN Study: A Double-blind, Multi-center, Two-part,<br />
Randomized, Placebo-controlled Study of the Safety,<br />
Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189<br />
in Early Rheumatoid Arthritis (<strong>RA</strong>) Patients with Active Joint<br />
Disease<br />
Thomas Jonassen<br />
Baricitinib Improves Bone Biomechanical Properties in<br />
Rheumatoid Arthritis (<strong>RA</strong>) – Results of a Prospective<br />
Interventional Study<br />
Arnd Kleyer<br />
A Phase 2, Randomized, Double-Blind, Placebo-Controlled,<br />
Mechanistic Insight and Dosage Optimization Study of the<br />
Efficacy and Safety of Dazodalibep (VIB4920/HZN4920)<br />
in Patients with Rheumatoid Arthritis Having Inadequate<br />
Response to Conventional/Biological DMARDs<br />
Alan Kivitz<br />
JAK Selectivity Did Not Affect to the Incidence of Malignancies<br />
in the Real-World Setting: Data from a Multicenter<br />
Observational Study in Japan<br />
Tomohisa Uchida
Change language